ClinicaliQ Trial Snapshot
- A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer — Recruiting • Phase I • Oncology • NCT05800665.
- What is being tested: RO7656594, a novel investigational agent, is undergoing evaluation for its safety profile, tolerability, pharmacokinetics (drug behaviour in the body), and preliminary anti-tumour activity in advanced or metastatic prostate cancer, with the aim of establishing optimal dosing for future….
- Patient eligibility overview: The trial includes participants with advanced or metastatic prostate cancer; specific inclusion/exclusion criteria would typically require confirmed diagnosis, adequate organ function, and prior treatment history, though detailed eligibility requires review of the full protocol.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and preliminary activity of RO7656594 in participants with advanced or metastatic prostate cancer. It will also identify recommended doses and regimens for RO7656594 for subsequent studies.
Eligibility Snapshot
- Key Inclusion Criteria: 1. Eastern Cooperative Oncology Group (ECOG) performance status ≤1. 2. Metastatic prostate adenocarcinoma without small-cell carcinoma or neuroendocrine features. 3. Prior therapy with a second-generation androgen receptor (AR)-targeted therapy (e.g., abiraterone, enzalutamide, apalutamide, darolutamide). 4. Prior therapy with a taxane regimen or are considered ineligible for treatment with a taxane regimen or have refused treatment with a taxane regimen, unless otherwise specified. 5. For participants with a known pathogenic breast cancer gene 1 (BRCA1) or BRCA2 mutation: prior therapy with a poly (adenosine diphosphate (ADP)-ribose) polymerase (PARP) inhibitor, or are considered ineligible for treatment with a PARP inhibitor, if such therapy is approved and available. Key
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.